EX-99.1 2 hcm-20230306xex99d1.htm EX-99.1

​

Exhibit 99.1

​

Graphic

​

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Monday, March 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2022 annual results of HUTCHMED on February 28, 2023, the following awards granted under the Long Term Incentive Plan (“LTIP”) on April 20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 3, 2023:-

​

Award Holders

Number of American depositary shares (“ADS”)

Person Discharging Managerial Responsibilities

​

Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)

50,431

Mr Johnny Cheng (Executive Director and Chief Financial Officer)

22,953

​

Total

73,384

​

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

​

​

​

(a)Dr Weiguo Su

​

​

​

​

​

​

​

1

Details of the person discharging managerial responsibilities/person closely associated

​

a)

​

Name

​

​

Dr Weiguo Su

2

Reason for the notification

​

a)

​

Position/status

​

​

Executive Director, Chief Executive Officer and Chief Scientific Officer

​

b)

​

Initial notification/Amendment

​

​

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

​

a)

​

Name

​

​

HUTCHMED (China) Limited

​

b)

​

LEI

​

​

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

​

a)

​

Description of the financial instrument, type of instrument

​

​

ADS each representing five Ordinary Shares of US$0.10

​

​

Identification code

​

ADS ISIN: US44842L1035

​

​

b)

​

Nature of the transaction

​

Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

​

​

c)

​

Price(s) and volume(s)

​

​

​

​

​

​

​

​

Price(s)

Volume(s)

​

​

​

​

Nil

50,431 ADS

​

​

​

​

​

​

​

​

d)

​

Aggregated information​

​

N/A

​

— Aggregated volume

​

​

— Price

​

​

​

e)

​

Date of the transaction

​

​

2023-03-03

​

f)

​

Place of the transaction

​

​

Outside a trading venue

​

​

​

​

(b)Mr Johnny Cheng

​

​

​

HIDDEN_ROW

​

​

​

​

1

Details of the person discharging managerial responsibilities/person closely associated

​

a)

​

Name

​

​

Mr Johnny Cheng

2

Reason for the notification

​

a)

​

Position/status

​

​

Executive Director and Chief Financial Officer

​

b)

​

Initial notification/Amendment

​

​

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

​

a)

​

Name

​

​

HUTCHMED (China) Limited

​

b)

​

LEI

​

​

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

​

a)

​

Description of the financial instrument, type of instrument

​

​

ADS each representing five Ordinary Shares of US$0.10

​

​

Identification code

​

ADS ISIN: US44842L1035

​

​

b)

​

Nature of the transaction

​

Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

​

​

c)

​

Price(s) and volume(s)

​

​

​

​

​

​

​

​

​

Price(s)

Volume(s)

​

​

​

​

Nil

22,953 ADS

​

​

​

​

​

​

​

​

​

d)

​

Aggregated information​

​

N/A

​

— Aggregated volume

​

​

— Price

​

​

​

e)

​

Date of the transaction

​

​

2023-03-03

​

f)

​

Place of the transaction

​

​

Outside a trading venue

​

​

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has about 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has been focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

CONTACTS

​

Investor Enquiries

​

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 306 4490

​

​

Media Enquiries

​

Americas – Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)
bmiles@soleburystrat.com

Europe – Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com

Asia – Zhou Yi, Brunswick

+852 9783 6894 (Mobile)
HUTCHMED@brunswickgroup.com

​

​

Nominated Advisor

​

Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited

+44 (20) 7886 2500

​